Pharming Group (OTCMKTS:PHGUF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday, March 10th.
According to Zacks, “Pharming Group NV develops innovative therapeutics for the treatment of genetic disorders, specialty products for surgical indications and nutritional products. The advanced technologies of the Company include innovative and validated platforms for the production of protein therapeutics, technology and processes for the purification and formulation of its products. Its primary product Ruconest (R) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with hereditary angioedema in the European Union countries, Norway, Iceland and Liechtenstein. Pharming Group NV is headquartered in Leiden, the Netherlands. “
Several other equities research analysts have also recently weighed in on PHGUF. ValuEngine cut Pharming Group from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Roth Capital reissued a “buy” rating on shares of Pharming Group in a research note on Wednesday, March 7th.
Shares of Pharming Group (OTCMKTS PHGUF) remained flat at $$1.46 during mid-day trading on Friday. The stock had a trading volume of 100 shares, compared to its average volume of 9,715. Pharming Group has a 12-month low of $0.31 and a 12-month high of $1.96. The company has a quick ratio of 0.99, a current ratio of 1.31 and a debt-to-equity ratio of 11.47. The stock has a market capitalization of $845.36, a P/E ratio of -13.27 and a beta of 2.50.
TRADEMARK VIOLATION NOTICE: “Pharming Group (PHGUF) Downgraded by Zacks Investment Research to “Hold”” was originally reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/03/18/pharming-group-phguf-downgraded-to-hold-at-zacks-investment-research.html.
Pharming Group Company Profile
Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.